ESR2 and neoplasm: TRIM16 is characterized by “anti-estrogen” activity, and its anti-estrogen action is mainly concentrated on ERβ, but the inhibitory effect of this receptor in the TC has not been confirmed, probably due to the biological characteristics of the tumor (18).